Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.34 |
| ▸ | MEN1 | O00255 | 2/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.34 |
| ▸ | LMNA | P02545 | 5/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.33 |
| ▸ | HTT | P42858 | 3/20 | 0.33 |
| ▸ | PKM | P14618 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.32 |
| ▸ | CNR2 | P34972 | 1/20 | 0.32 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.32 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.32 |
| ▸ | DHPS | P49366 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5445142 | 0.93 | EGLN1 (0.39) | ALDH1A1MEN1KMT2ALMNASMN1; SMN2 | |
| SCHEMBL5450208 | 0.93 | EGLN1 (0.37) | ALDH1A1MEN1KMT2ASMN1; SMN2AKR1B1 | |
| SCHEMBL13672777 | 0.92 | AKR1B1 (0.41) | ALDH1A1MEN1KMT2ALMNASMN1; SMN2 | |
| SCHEMBL5438443 | 0.90 | GAA (0.42) | ALDH1A1KMT2ALMNASMN1; SMN2EGLN1 | |
| SCHEMBL5437380 | 0.89 | CENPE (0.38) | ALDH1A1SMN1; SMN2 | |
| SCHEMBL5446694 | 0.88 | MAOB (0.35) | ALDH1A1LMNAAKR1B1 | |
| SCHEMBL5446606 | 0.88 | WDR5 (0.36) | ALDH1A1MEN1KMT2ALMNAEGLN1 | |
| SCHEMBL5446667 | 0.88 | EGLN1 (0.37) | ALDH1A1MEN1KMT2ALMNASMN1; SMN2 | |
| SCHEMBL5444577 | 0.87 | WDR5 (0.40) | ALDH1A1LMNA | |
| SCHEMBL5437421 | 0.87 | AKR1B1 (0.36) | ALDH1A1L3MBTL1HTTAKR1B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070179196-A1 | Hiv integrase inhibitors | MERCK SHARP & DOHME CORP. | 2007-08-02 | — | — | US | claimed |
| EP-1725556-A1 | HIV INTEGRASE INHIBITORS | Merck & Co., Inc. (US) | 2006-11-29 | — | — | EP | claimed |
| WO-2005087768-A1 | HIV INTEGRASE INHIBITORS | MERCK & CO., INC. (US) | 2005-09-22 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070179196-A1 | Hiv integrase inhibitors | REV1, TYMP, POLR2H | ALDH1A1 1500/4885MEN1 4754/4885KMT2A 1470/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.